<div id="readability-page-1"><p><span>Janux Therapeutics (NASDAQ:JANX - Get Free Report)</span>'s stock had its &#34;outperform&#34; rating reissued by investment analysts at Wedbush in a research note issued on Tuesday,RTT News reports. They presently have a $45.00 target price on the stock, down from their previous target price of $76.00. Wedbush's target price suggests a potential upside of 183.73% from the company's current price.</p><p>Several other analysts have also commented on JANX. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Janux Therapeutics in a research report on Wednesday, October 8th. Piper Sandler started coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an &#34;overweight&#34; rating and a $42.00 target price for the company. Bank of America lowered their target price on shares of Janux Therapeutics from $58.00 to $49.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday. Barclays upped their price target on Janux Therapeutics from $47.00 to $48.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, November 7th. Finally, HC Wainwright lowered their price objective on Janux Therapeutics from $70.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. One equities research analyst  has rated the stock with a Strong Buy rating, fourteen have assigned  a Buy rating, two have assigned  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $67.36.</p><div><p><span></span><span>Get <strong>Janux Therapeutics</strong> alerts:</span></p></div><p><b>Get Our Latest Stock Report on JANX</b></p><h2>Janux Therapeutics Stock Down 53.3%</h2><p>JANX stock traded down $18.13 during trading on Tuesday, hitting $15.86. The company had a trading volume of 15,930,781 shares, compared to its average volume of 1,150,156. Janux Therapeutics has a 52-week low of $15.77 and a 52-week high of $71.71. The company has a 50 day simple moving average of $27.15 and a 200-day simple moving average of $25.37. The firm has a market capitalization of $953.98 million, a P/E ratio of -9.44 and a beta of 2.82. </p><p>Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million.  Sell-side analysts forecast that  Janux Therapeutics will post -1.38 earnings per share for the current year. </p><h2>Insider Buying and Selling at Janux Therapeutics</h2><p>In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of the firm's stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total value of $500,949.90. Following the sale, the insider directly owned 82,139 shares of the company's stock, valued at approximately $2,469,098.34. This trade represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 29.40% of the stock is currently owned by company insiders. </p><h2>Hedge Funds Weigh In On Janux Therapeutics</h2><p>A number of hedge funds have recently made changes to their positions in the company. Alyeska Investment Group L.P. lifted its position in shares of  Janux Therapeutics by 64.2% in the third quarter. Alyeska Investment Group L.P. now owns 424,845 shares of the company's stock valued at $10,383,000 after acquiring an additional 166,167 shares in the last quarter.  Verition Fund Management LLC raised its stake in  Janux Therapeutics by 240.3% in the 3rd quarter. Verition Fund Management LLC now owns 40,731 shares of the company's stock valued at $995,000 after purchasing an additional 28,761 shares during the last quarter.  Jain Global LLC purchased a new position in  Janux Therapeutics in the 3rd quarter valued at $241,000.  Orbimed Advisors LLC boosted its stake in  Janux Therapeutics by 45.9% during the 3rd quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company's stock worth $43,163,000 after purchasing an additional 555,800 shares during the last quarter.  Finally, ADAR1 Capital Management LLC grew its holdings in shares of  Janux Therapeutics by 7.4% during the third quarter. ADAR1 Capital Management LLC now owns 351,032 shares of the company's stock worth $8,579,000 after buying an additional 24,044 shares in the last quarter. Institutional investors and hedge funds own  75.39% of the company's stock. </p><h2>About Janux Therapeutics</h2> (Get Free Report)<p>Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.</p><h2>Read More</h2><ul><li>Five stocks we like better than Janux Therapeutics</li><li>The Risks of Owning Bonds</li><li>Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>Checkmate in the Cloud: ServiceNow's Shopping Spree</li><li>Russell 2000 Index, How Investors Use it For Profitable Trading</li><li>The Contrarian Case for MSTR Amid MSCI Delisting Debacle</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFOWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Janux Therapeutics Right Now?</h2><p>Before you consider Janux Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.</p><p>While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

JANX

<p>Wedbush reaffirmed its "outperform" rating for Janux Therapeutics (NASDAQ:JANX) with a revised target price of $45.00, down from $76.00, suggesting a potential upside of 183.73%. Other analysts have mixed ratings, with some lowering their target prices. Janux's stock fell 53.3% to $15.86. The company reported better-than-expected earnings and revenue for the recent quarter. Insider trading and hedge fund activities were also noted.</p>

Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush